Amarantus Announces Issuance of Australian Patent No. 61/057,713 Covering Eltoprazine Treatment of Parkinson’s Disease and ...
October 29 2015 - 09:58AM
Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology
company developing therapeutic and diagnostic product candidates in
orphan indications and neurology, today announced the issuance of
Australian patent no. 61/057,713 covering the use of Eltoprazine
for the treatment of various neurological and mental disorders,
including Parkinson’s disease, Alzheimer’s disease and several
other mental disorders.
“This patent issuance covering Eltoprazine for
the treatment of Parkinson’s disease and Alzheimer’s disease
represents a significant addition to the international intellectual
property position covering Eltoprazine,” said Gerald E.
Commissiong, President & CEO of Amarantus. “As the company
evaluates business development opportunities, we believe the
continued expansion of the patent estate covering Eltoprazine will
be important.”
About Eltoprazine
Eltoprazine is a small molecule 5HT1A/1B partial
agonist in clinical development for the treatment of Parkinson's
disease levodopa-induced dyskinesia (PD-LID), adult attention
deficit hyperactivity disorder (ADHD) and Alzheimer’s aggression.
Eltoprazine has been evaluated in over 680 human subjects to date,
and has a well-established safety profile. Eltoprazine was
originally developed by Solvay Pharmaceuticals for the treatment of
aggression. Upon Solvay's merger with Abbott Pharmaceuticals, the
eltoprazine program was out-licensed to PsychoGenics.
PsychoGenics licensed eltoprazine to Amarantus following successful
proof-of-concept trials in PD-LID and adult ADHD.
About Amarantus BioScience Holdings,
Inc.
Amarantus BioScience Holdings (OTCQX:AMBS) is a
biotechnology company developing treatments and diagnostics for
diseases in the areas of neurology and orphan diseases. The Company
has an exclusive worldwide license to intellectual property rights
associated to Engineered Skin Substitute (ESS), an orphan drug
designated autologous full thickness skin replacement product in
development for the treatment of adult severe burns currently
preparing to enter Phase 2 clinical studies. The Company is
currently evaluating human clinical data from previously conducted
studies in pediatric severe burns and Congenital Giant Hairy Nevus
to support clinical development expansion into those areas.
AMBS also has development rights to eltoprazine, a small molecule
currently in a Phase 2b clinical program for Parkinson's disease
levodopa-induced dyskinesia with the potential to expand into adult
ADHD and Alzheimer's aggression. AMBS owns the intellectual
property rights to a therapeutic protein known as
mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is
developing MANF as a treatment for orphan ophthalmic disorders,
initially in retinitis pigmentosa (RP) and retinal artery occlusion
(RAO). AMBS also owns the discovery of neurotrophic factors
(PhenoGuard™) that led to MANF's discovery.
AMBS' Diagnostics division owns the rights to
MSPrecise®, a proprietary next-generation DNA sequencing (NGS)
assay for the identification of patients with relapsing-remitting
multiple sclerosis (RRMS) at first clinical presentation, has an
exclusive worldwide license to the Lymphocyte Proliferation test
(LymPro Test®) for Alzheimer's disease, which was developed by
Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and
owns intellectual property for the diagnosis of Parkinson's disease
(NuroPro).
For further information please visit
www.Amarantus.com, or connect with the Company on Facebook,
LinkedIn, Twitter and Google+.
Forward-Looking Statements
Certain statements, other than purely historical
information, including estimates, projections, statements relating
to our business plans, objectives, and expected operating results,
and the assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
Investor and Media Contact:
Ascendant Partners, LLC
Fred Sommer
732-410-9810
fred@ascendantpartnersllc.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2023 to Mar 2024